The improvement of large high-density lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight loss

EXCLI Journal

Volumn 15, Issue , 2016, Pages 166-176

  Finelli, C ^a   Crispino, P ^b   Gioia, S ^a   La Sala, N ^a   D'amico L ^a   La Grotta, M ^a   Miro, O ^a   Colarusso, D ^b  

^a Stella Maris Mediterraneum Foundation   (Italy)

^b ASP Azienda Sanitaria Potenza   (Italy)

Author keywords

HDL; Low carbohydrate diet and weight loss; Obesity

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIETARY INTAKE; HUMAN; ITALY; LIPID BLOOD LEVEL; LIPID METABOLISM; LOW CARBOHYDRATE DIET; MAJOR CLINICAL STUDY; NUTRITIONAL HEALTH; TWO DIMENSIONAL GEL ELECTROPHORESIS; WEIGHT REDUCTION;

EID: 84975726033     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2015-642     Document Type: Article

References (51)

1. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of highdensity lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-91.
2. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290:2030-40.
3. Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42:418-27.
4. Chyu KY, Shah PK. HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Front Pharmacol. 2015;6:187.
5. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43-53.
6. Dullens SP, Plat J, Mensink RP. Increasing apoA-I production as a target for CHD risk reduction. Nutr Metab Cardiovasc Dis. 2007;17:616-28.
7. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S76-99.
8. Elshazly MB, Quispe R, Michos ED, Sniderman AD, Toth PP, Banach M, et al. Patient-level discordance in population percentiles of the total cholesterol to highdensity lipoprotein cholesterol ratio in comparison with low-density lipoprotein cholesterol and nonhigh- density lipoprotein cholesterol: the very large database of lipids study (VLDL-2B). Circulation. 2015;132:667-76.
9. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015;31:1-13.
10. Filippatos TD, Elisaf MS. High density lipoprotein and cardiovascular diseases. World J Cardiol. 2013;5: 210-4.
11. Finelli C, Tarantino G. Non-alcoholic fatty liver disease, diet and gut microbiota. EXCLI J. 2014;13:461-90.
12. Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, et al. Assessment of physical activity in an outpatient obesity clinic in southern Italy: results from a standardized questionnaire. Nutr Metab Cardiovasc Dis. 2006;16:168-73.
13. Finelli C, Padula MC, Martelli G, Tarantino G. Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? World J Gastroenterol. 2014;20:16649-64.
14. Hu T, Yao L, Reynolds K, Whelton PK, Niu T, Li S, et al. The effects of a low-carbohydrate diet vs. a lowfat diet on novel cardiovascular risk factors: a randomized controlled trial. Nutrients. 2015;7:7978-94.
15. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985-3023.
16. Joshi PH, Toth PP, Lirette ST, Griswold ME, Massaro JM, Martin SS, et al. Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol. 2016;23:41-9.
17. Kim DS, Burt AA, Rosenthal EA, Ranchalis JE, Eintracht JF, Hatsukami TS, et al. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc. 2014;3(3):e000902.
18. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res. 2013;54:2950-63.
19. Kouda K, Nakamura H, Fujita Y, Hamada M, Kajita E, Nakatani Y, et al. HDL subclasses are heterogeneous in their associations with body fat, as measured by dual-energy X-ray absorptiometry: the Kitakata Kids Health Study. Clin Chim Acta. 2015;444:101-5.
20. Lee JW, Kim EY, Yoo HM, Park CH, Song KY. Changes of lipid profiles after radical gastrectomy in patients with gastric cancer. Lipids Health Dis. 2015;14:21.
21. Liu X, Tao L, Cao K, Wang Z, Chen D, Guo J, et al. Association of high-density lipoprotein with development of metabolic syndrome components: a fiveyear follow-up in adults. BMC Public Health. 2015;15:412.
22. Madahian S, Navab KD, Pourtabatabaei N, Seyedali S, Safar S, Vazirian S, et al. Inflammation, high density lipoprotein and endothelium. Curr Med Chem. 2014;21:2902-9.
23. Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Marado D, Palavra F, Pinto R, et al. Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm. 2013; 2013:612038.
24. Mente A, Chalcraft K, Ak H, Davis AD, Lonn E, Miller R, et al. the relationship between trimethylaminen- oxide and prevalent cardiovascular disease in a multiethnic population living in Canada. Can J Cardiol. 2015;31:1189-94.
25. Miller NE. Cholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker? Front Pharmacol. 2015;6:145.
26. Phillips CM, Perry IJ. Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: Does size matter? Atherosclerosis. 2015;242:399-406.
27. Reina SA, Llabre MM, Allison MA, Wilkins JT, Mendez AJ, Arnan MK, et al. HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;243:314-9.
28. Rohatgi A. High-density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity. Prog Cardiovasc Dis. 2015;58:32-40.
29. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256-67.
30. Rosenson RS, Davidson MH, Le NA, Burkle J, Pourfarzib R. Underappreciated opportunities for highdensity lipoprotein particles in risk stratification and potential targets of therapy. Cardiovasc Drugs Ther. 2015;29:41-50.
31. Russo GT, Giandalia A, Romeo EL, Alibrandi A, Horvath KV, Asztalos BF, et al. Markers of systemic inflammation and apo-ai containing hdl subpopulations in women with and without diabetes. Int J Endocrinol. 2014;2014:607924.
32. Sacks FM, Carey VJ, Anderson CA, Miller ER 3rd, Copeland T, Charleston J, et al. Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. JAMA. 2014; 312:2531-41.
33. Samino S, Vinaixa M, Díaz M, Beltran A, Rodríguez MA, Mallol R, et al. Metabolomics reveals impaired maturation of HDL particles in adolescents with hyperinsulinaemic androgen excess. Sci Rep. 2015;5: 11496.
34. Savastano S, Di Somma C, Colao A, Barrea L, Orio F, Finelli C, et al. Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor- 1 status. Growth Horm IGF Res. 2015;25:28-33.
35. Savolainen MJ. Epidemiology: disease associations and modulators of HDL-related biomarkers. Handb Exp Pharmacol. 2015;224:259-83.
36. Scharnagl H, Heuschneider C, Sailer S, Kleber ME, März W, Ritsch A. Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. Eur J Clin Invest. 2014;44: 395-401.
37. Schröder H, Covas MI, Marrugat J, Vila J, Pena A, Alcántara M, et al. Use of a three-day estimated food record, a 72-hour recall and a food-frequency questionnaire for dietary assessment in a Mediterranean Spanish population. Clin Nutr. 2001;20:429-37.
38. Schwendeman A, Sviridov DO, Yuan W, Guo Y, Morin EE, Yuan Y, et al. The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. J Lipid Res. 2015;56:1727-37.
39. Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Kimoto E, Koyama H, et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis. 2009;202:582-8.
40. Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS, Krauss RM. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obesity (Silver Spring). 2009;17:1768-75.
41. Sprandel MC, Hueb WA, Segre A, Ramires JA, Kalil-Filho R, Maranhão RC. Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:107.
42. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514(7521):181-6.
43. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015;10:889-902.
44. Tarantino G, Scopacasa F, Colao A, Capone D, Tarantino M, Grimaldi E, et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17: 5280-8.
45. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care. 2014;37:2909-18.
46. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015;102:780-90.
47. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380 (9841):572-80.
48. Volek JS, Ballard KD, Silvestre R, Judelson DA, Quann EE, Forsythe CE, et al. Effects of dietary carbohydrate restriction versus low-fat diet on flowmediated dilation. Metabolism. 2009;58:1769-77.
49. Warnick GR. Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. Clin Chem Lab Med. 2000;38:287-300.
50. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl). 2006;84:276-94.
51. Zhang C, Gao F, Luo H, Zhang CT, Zhang R. Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity. Cardiovasc Diabetol. 2015;14:79.